Ocugen Inc. (OCGN): Price and Financial Metrics

Ocugen Inc. (OCGN): $1.00

0.06 (-5.98%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add OCGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#248 of 356

in industry

OCGN Price/Volume Stats

Current price $1.00 52-week high $1.28
Prev. close $1.06 52-week low $0.35
Day low $0.91 Volume 15,039,900
Day high $1.04 Avg. volume 5,581,864
50-day MA $0.57 Dividend yield N/A
200-day MA $0.50 Market Cap 255.63M

OCGN Stock Price Chart Interactive Chart >


Ocugen Inc. (OCGN) Company Bio


Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.


OCGN Latest News Stream


Event/Time News Detail
Loading, please wait...

OCGN Latest Social Stream


Loading social stream, please wait...

View Full OCGN Social Stream

Latest OCGN News From Around the Web

Below are the latest news stories about OCUGEN INC that investors may wish to consider to help them evaluate OCGN as an investment opportunity.

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP). “This news brings us even clo

Yahoo | December 21, 2023

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT desig

Yahoo | December 19, 2023

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the ArMaDa Phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (dAMD). “OCU410, our first-in-class modifier gene therapy for dAMD, addres

Yahoo | December 13, 2023

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking

Yahoo | November 29, 2023

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […]

Yahoo | November 10, 2023

Read More 'OCGN' Stories Here

OCGN Price Returns

1-mo 83.05%
3-mo 153.10%
6-mo 118.82%
1-year 2.24%
3-year -88.36%
5-year -87.18%
YTD 73.91%
2023 -55.77%
2022 -71.43%
2021 148.63%
2020 251.92%
2019 -90.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!